Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Bold solutions with the

CapacitytoCure

At Poseida Therapeutics, we are boldly developing new solutions to redefine treatment paradigms for life-threatening cancers and genetic diseases. We have designed our genetic engineering technologies to represent the future of innovation in cell and gene therapies, giving new hope to patients.

At Poseida Therapeutics, we are boldly developing new solutions to redefine treatment paradigms for life-threatening cancers and genetic diseases. We have designed our genetic engineering technologies to represent the future of innovation in cell and gene therapies, giving new hope to patients.

r-and-d-day-violator-img

x

Audio

International Myeloma Society (IMS) Fireside Chat

Tune in to hear leading multiple myeloma experts discuss interim
Phase 1 results for allogeneic CAR-T therapy P-BCMA-ALLO1 and
the potential significance for multiple myeloma patients.

A close image of a gloved hand holding an orange cap to a cell culture flask. The flask stands upright with a pipette poised above the opening.
A close image of a gloved hand holding an orange cap to a cell culture flask. The flask stands upright with a pipette poised above the opening.

TECHNOLOGY

A Suite of Differentiated Genetic Engineering Platforms

Our non-viral piggyBac® DNA Delivery System inserts large genetic payloads into the genome. Our Cas-CLOVER™ Site-Specific Gene Editing System can be leveraged to make accurate site-specific deletions, insertions, and knock-ins in multiple cell types.

DISCOVER OUR TECHNOLOGY

Video

Thomas G. Martin, M.D., discusses case of reactivation of CAR-T Therapy with a T-Cell Engager in Relapsed Multiple Myeloma

Thomas G. Martin, M.D., discusses case of reactivation of CAR-T Therapy with a T-Cell Engager in Relapsed Multiple Myeloma

A Poseida employee stands at the front of a full conference room presenting slides displayed on a screen. Several employees sitting around the conference table look at the slides.
A Poseida employee stands at the front of a full conference room presenting slides displayed on a screen. Several employees sitting around the conference table look at the slides.

ABOUT US

Poseida Stands Apart

Our leadership team combines long-standing scientific expertise with the strategic insight needed to advance the company forward and deliver novel therapeutics for patients.

Meet the Team

Partner of Choice
in Allogeneic CAR-T


Backed by powerful proprietary non-viral
technologies and validation from external partners,
Poseida is a leading clinical stage allogeneic
cell therapy and genetic medicines company advancing
differentiated treatments for patients with cancer and rare diseases.

ABOUT OUR PARTNERS

Poseida - Cell Type Matters
Poseida - Cell Type Matters

PIPELINE

Cell Type Matters

Our gene editing technologies and delivery platforms allow us to target many different cell types to treat cancer and genetic diseases. By focusing on specific cell populations, we can potentially advance fully allogeneic CAR-T therapies with an early memory phenotype for patients fighting cancer or develop functional cures for rare genetic diseases.

View our pipeline

Latest News and Updates

News-Center-space-Wide

Space, the final frontier…

By Mark Gergen, Executive Chairman

LinkedIn

 | 

September 17, 2024
News-partnership-Tall
News-partnership-Wide

Progress and the Power of Partnership – The Sequel

By Mark Gergen, Executive Chairman

LinkedIn

 | 

September 5, 2024

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Press Release

 | 

November 5, 2024

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

Press Release

 | 

October 24, 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

Press Release

 | 

October 17, 2024
View all news